Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Raw Materials (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Raw Materials for 14 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials rose 9.33% to $20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a 9.33% increase, with the full-year FY2025 number at $20.9 million, up 9.33% from a year prior.
  • Raw Materials was $20.9 million for Q4 2025 at Lemaitre Vascular, roughly flat from $21.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $21.7 million in Q2 2025 to a low of $4.7 million in Q3 2021.
  • A 5-year average of $15.6 million and a median of $18.3 million in 2023 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: decreased 7.92% in 2021, then surged 186.37% in 2022.
  • Lemaitre Vascular's Raw Materials stood at $5.9 million in 2021, then soared by 151.12% to $14.9 million in 2022, then increased by 22.8% to $18.3 million in 2023, then grew by 4.23% to $19.1 million in 2024, then grew by 9.33% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Raw Materials are $20.9 million (Q4 2025), $21.0 million (Q3 2025), and $21.7 million (Q2 2025).